Insider · CIK 0001235598

FRATES JAMES M

Reports to the SEC for 4 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001235598

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-10	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−9,768 sh	$32.27	−$315K	234,667
2026-09-10	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−1,042 sh	$33.23	−$34.6K	233,625
2026-08-18	AMLXAmylyx Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+22.8K sh	—	—	244,435
2026-03-05	AMLXAmylyx Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+96K sh	—	—	261,628
2026-03-05	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+144K sh	—	—	143,985
2026-03-02	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−7,909 sh	$14.52	−$115K	165,638
2026-02-02	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−3,557 sh	$14.65	−$52.1K	173,547
2026-01-06	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−3,326 sh	$11.11	−$37K	177,104
2025-09-30	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−10.6K sh	$14.65	−$155K	280,430
2025-07-31	Sage Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−21.5K sh	—	—	0
2025-07-31	Sage Therapeutics, Inc.U Disposition from Tender	Director	UDisposition from Tender	−2,845 sh	—	—	0
2025-07-31	Sage Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−19.2K sh	—	—	0
2025-06-11	Sage Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+21.5K sh	—	—	21,500
2025-03-31	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−10.9K sh	$3.47	−$37.8K	290,988
2025-03-06	AMLXAmylyx Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+68.4K sh	—	—	301,884
2025-03-06	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+103K sh	—	—	102,630
2025-01-03	Sage Therapeutics, Inc.Stock Options (Right to buy)A Award	Director	AAward	+19.2K sh	—	—	19,154
2024-09-12	AMLXAmylyx Pharmaceuticals, Inc.P Purchase	Chief Financial Officer	PPurchase	+40K sh	$2.53	+$101K	233,464
2024-06-10	Sage Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+12.5K sh	—	—	12,500
2024-04-16	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+120K sh	—	—	120,000
2024-04-16	AMLXAmylyx Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+91.2K sh	—	—	225,964
2024-03-05	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−1,792 sh	$18.73	−$33.6K	134,784
2024-02-26	AMLXAmylyx Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+40K sh	—	—	152,035
2024-02-26	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+60K sh	—	—	60,000
2024-01-09	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−2,716 sh	$16.33	−$44.3K	112,035
2024-01-03	Sage Therapeutics, Inc.Stock Options (Right to buy)A Award	Director	AAward	+4,925 sh	—	—	4,925
2023-10-31	AMLXAmylyx Pharmaceuticals, Inc.G Gift	Chief Financial Officer	GGift	+11.1K sh	—	—	11,072
2023-08-23	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−18.2K sh	—	—	363,835
2023-08-23	AMLXAmylyx Pharmaceuticals, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+18.2K sh	$6.88	+$125K	106,341
2023-08-23	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−18.2K sh	—	—	363,835
2023-08-23	AMLXAmylyx Pharmaceuticals, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+18.2K sh	$6.88	+$125K	73,841
2023-06-15	Sage Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2023-05-16	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−32.5K sh	—	—	382,000
2023-05-16	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−500 sh	$27.60	−$13.8K	55,676
2023-05-16	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−32K sh	$26.93	−$862K	56,176
2023-05-16	AMLXAmylyx Pharmaceuticals, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+32.5K sh	$6.88	+$224K	88,176
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−1,704 sh	$32.46	−$55.3K	34,009
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+97.5K sh	—	—	97,500
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+21.7K sh	—	—	55,676
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+97.5K sh	—	—	97,500
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−30.8K sh	$31.86	−$981K	3,213
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+32.5K sh	$6.88	+$224K	66,509
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−32.5K sh	—	—	414,500
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−1,704 sh	$32.46	−$55.3K	1,509
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc.A Award	Chief Financial Officer	AAward	+21.7K sh	—	—	23,176
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	−30.8K sh	$31.86	−$981K	35,713
2023-01-06	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	+1,836 sh	$36.08	+$66.2K	34,831
2023-01-06	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Chief Financial Officer	SSale	+822 sh	$36.79	+$30.2K	34,009
2022-12-30	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,000 sh	—	—	447,000
2022-12-30	AMLXAmylyx Pharmaceuticals, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,000 sh	$6.88	+$34.4K	36,667

Recent filings

Accepted (ET)
Sep 144
FRATES JAMES M0001193125-26-390509
SEC(opens sec.gov)
Aug 204
FRATES JAMES M0001193125-26-359679
SEC(opens sec.gov)
Mar 94
FRATES JAMES M0001193125-26-098438
SEC(opens sec.gov)
Mar 44
FRATES JAMES M0001193125-26-091438
SEC(opens sec.gov)
Feb 44
FRATES JAMES M0001193125-26-037553
SEC(opens sec.gov)
Jan 84
FRATES JAMES M0001193125-26-007669
SEC(opens sec.gov)
Oct 24
FRATES JAMES M0001193125-25-228341
SEC(opens sec.gov)
Jul 314
FRATES JAMES M0000950170-25-100653
SEC(opens sec.gov)
Jun 134
FRATES JAMES M0001562180-25-004791
SEC(opens sec.gov)
Apr 24
FRATES JAMES M0000950170-25-049581
SEC(opens sec.gov)
Mar 104
FRATES JAMES M0000950170-25-036707
SEC(opens sec.gov)
Jan 64
FRATES JAMES M0001562180-25-000163
SEC(opens sec.gov)
Sep 164
FRATES JAMES M0000950170-24-106910
SEC(opens sec.gov)
Sep 54/A
FRATES JAMES M0000950170-24-104191
SEC(opens sec.gov)

Companies

Address

C/O AMYLYX PHARMACEUTICALS, INC. 55 CAMBRIDGE PARKWAY, SUITE 6W

CAMBRIDGE, MA, 02142